PGPIPN
A milk-derived hexapeptide from bovine beta-casein with immunomodulatory, anticancer, and hepatoprotective properties studied primarily in ovarian cancer and liver disease models.
What is PGPIPN?
PGPIPN (Pro-Gly-Pro-Ile-Pro-Asn) is a six-amino-acid peptide corresponding to residues 63-68 of bovine beta-casein. It is naturally encrypted within milk protein and released during enzymatic digestion. Its three proline residues are thought to make it relatively resistant to digestive enzymes. It has been detected in the small intestine of healthy adults after they drank casein, and the Anhui group reported finding it in mouse blood an hour after an oral dose — though only as an unpublished aside. No human absorption or blood-level study exists. Originally identified for its immunomodulatory properties — enhancing macrophage phagocytosis and lymphocyte proliferation — it has since been studied for anticancer effects (particularly against ovarian cancer) and for protecting the liver from alcohol-induced damage.
What PGPIPN Is Investigated For
PGPIPN is a milk-derived hexapeptide from bovine beta-casein studied for ovarian cancer growth suppression (via BCL2-mediated apoptosis), overcoming cisplatin resistance, immune enhancement, and hepatoprotection against alcohol-induced liver damage. The strongest preclinical signal comes from a single 2013 ovarian cancer xenograft study (six mice per group, peptide injected intraperitoneally), where high-dose PGPIPN reduced tumor volume by ~68% — exceeding the 42% reduction seen with 5-fluorouracil in the same study — with selective cytotoxicity toward cancer over normal cells in vitro. Cisplatin-sensitization via HSF1/HSP70 downregulation and liver-protection via the PERK/eIF-2α ER stress pathway are additional mechanistically characterized findings. No human clinical trials have been conducted in any indication, and the critical caveat on the entire evidence base is that nearly all of the preclinical work originates from a single research program at Anhui Medical University in China. Outside laboratories have looked only at its immune effects — a Paris group in the late 1980s and an Athens group in 2006 — and none has tested the cancer or liver findings. The proline-rich structure plausibly supports oral bioavailability, but human pharmacokinetic data is absent. This is a candidate molecule, not a therapeutic — substituting it for evidence-based oncology or hepatology care is not appropriate.
History & Discovery
PGPIPN was identified as a bioactive fragment of bovine beta-casein corresponding to residues 63–68 of the parent protein, released during enzymatic digestion of milk by gastrointestinal proteases. The hexapeptide belongs to the broader category of food-derived bioactive peptides — sequences encrypted within dietary proteins that become biologically active only after proteolytic release in the gut. The first characterization came from the Jolles protein laboratory at the CNRS and Universite de Paris V in the late 1980s, which reported that immune-stimulating peptides released during digestion of human and bovine caseins boosted macrophage phagocytosis in culture and protected mice against Klebsiella pneumoniae infection, and described a strategic zone in beta-casein holding both immune-stimulating and opioid peptides; the unusual proline density (three of six residues) made it a natural candidate for studies of digestion-resistant peptides with potential systemic exposure after oral intake. Most of the subsequent work — anticancer activity in ovarian cancer cell lines and xenografts, attenuation of cisplatin resistance through HSF1/HSP70 modulation, and protection against alcoholic liver injury — has come from a research program at Anhui Medical University in China across roughly the 2010s and early 2020s. The footprint is mechanistically interesting and reasonably broad in terms of pathway coverage, but it remains heavily concentrated within one institutional research program, has not generated human clinical trial data in any indication, and has not produced the kind of independent multi-laboratory replication that would lift PGPIPN out of the early preclinical category.
How It Works
PGPIPN is a tiny, digestion-resistant peptide from milk protein that works through multiple pathways. In cancer cells, it triggers programmed cell death by suppressing the survival protein BCL2 and can help overcome chemotherapy resistance. In the immune system, it boosts the activity of macrophages (immune cells that engulf pathogens) and promotes lymphocyte proliferation. In the liver, it reduces inflammation, oxidative stress, and the ER stress response that drives alcohol-related damage.
PGPIPN exerts anticancer effects primarily through apoptosis induction: it downregulates BCL2 (anti-apoptotic) while upregulating Bax (pro-apoptotic), shifting the BCL2/Bax ratio toward programmed cell death, measured in tumors from SKOV3-derived xenografts. It inhibits invasion and metastasis by repressing MTA1 (metastasis-associated protein 1) and upregulating NM23H1 (metastasis suppressor). In cisplatin-resistant cells, PGPIPN reduces HSF1/HSP70 signaling, downregulates MDR1 (P-glycoprotein) and ERCC1 (DNA repair protein), and increases cisplatin-induced G2/M cell-cycle arrest. Blocking HSP70 reduced or removed the sensitizing effect. The authors describe the interaction as synergistic, but no formal combination-index analysis was reported, and all of this work was done in cell culture. Hepatoprotective effects involve attenuation of ER stress through the PERK/eIF-2alpha pathway, reduction of pro-inflammatory cytokines (TNF-alpha, IL-1beta, IL-6), decreased oxidative stress markers (MDA), increased antioxidant enzyme activity (SOD, GSH-PX), and regulation of lipid metabolism via ACC phosphorylation and PPAR-gamma upregulation. Immunomodulatory activity: the earliest work reported that the peptide boosted macrophage phagocytosis of sheep red blood cells in culture and protected mice against Klebsiella pneumoniae infection. The Anhui group later reported stronger macrophage phagocytosis and lymphocyte proliferation in rats and mice, mostly in Chinese-language journals. The effect is not uniformly stimulatory: in macrophages from newly weaned piglets, PGPIPN suppressed the urokinase plasminogen activator system and superoxide production.
Evidence Snapshot
Human Clinical Evidence
None. No human clinical trials have been published for PGPIPN in any indication.
Animal / Preclinical
Moderate. One xenograft study (six nude mice per group, dosed by intraperitoneal injection) showed dose-dependent suppression of ovarian tumors, up to 68% smaller by volume. Two mouse studies showed liver protection, one in a 12-week chronic alcohol model and one over 10 days of acute injury. Immune enhancement demonstrated in rat and mouse models. However, most studies originate from a single research group.
Mechanistic Rationale
Moderate. Multiple molecular pathways have been identified (BCL2/Bax, HSF1/HSP70, MTA1/NM23H1, PERK/eIF-2alpha), but the primary direct molecular target remains unclear. Mechanisms are plausible but not yet independently replicated.
Research Gaps & Open Questions
What the current literature has not yet settled about PGPIPN:
- 01Independent replication outside the originating Anhui Medical University research program — nearly all efficacy and mechanistic claims trace to a single institutional research orbit.
- 02Human pharmacokinetics — absorption (particularly the proline-resistance hypothesis for oral bioavailability), distribution to ovarian or hepatic tissue, metabolism, and clearance have not been characterized in humans.
- 03Phase I human safety — no first-in-human dosing studies have been conducted in any indication.
- 04Direct molecular target — although multiple downstream pathways are implicated (BCL2/Bax, HSF1/HSP70, MTA1/NM23H1, PERK/eIF-2alpha), the primary receptor or upstream binding partner that initiates these effects remains unidentified.
- 05Selectivity for cancer cells over normal cells — preliminary cell-culture data suggests selective cytotoxicity, but the threshold for normal-tissue toxicity in vivo across organ systems has not been mapped.
- 06Cell-line authentication — LO2, used as the normal liver control in the selectivity experiments and as the fatty-liver cell model, is listed in cell-line registries as a HeLa derivative, so those findings need repeating in authenticated normal cells.
- 07Immune contribution to tumor control — the only xenograft study used athymic nude mice, which lack a functioning adaptive immune system, so it cannot show whether PGPIPN's immune effects contribute to its anticancer activity.
- 08Dietary relevance — PGPIPN has been detected in human jejunal fluid after casein intake and in kefir and aged cheese, but whether dietary PGPIPN reaches the bloodstream or does anything in people is unknown.
- 09In vivo cisplatin combination — the HSF1/HSP70 resensitization data are entirely cell-culture; no animal study has tested PGPIPN together with cisplatin.
- 10Comparative efficacy versus established cisplatin-resensitization strategies — PGPIPN's preclinical synergy with cisplatin has not been benchmarked against other investigational chemosensitizers.
Forms & Administration
PGPIPN has only been used in research settings. In animal studies, it was administered via oral gavage at doses ranging from 0.025-4 mg/kg body weight (liver studies) or at 0.15-15 micromolar in the liver and cisplatin cell-culture work. In the single xenograft study, mice were injected intraperitoneally with 0.2 mL of a 0.25 or 0.50 g/L solution every other day for four weeks. The proline-rich structure is proposed to resist digestion, but oral bioavailability has never been properly measured. No human dosing has been established. PGPIPN is not commercially available as a therapeutic agent. All injectable peptides should only be administered under the guidance of a qualified healthcare provider. Never self-administer without clinician oversight.
Dosing & Protocols
The ranges below reflect protocols commonly discussed in the literature and by clinicians — not a prescription. Actual dosing for any individual should be determined by a qualified healthcare provider who knows the patient.
Typical Range
There is no human dosing convention for PGPIPN because no human studies have been conducted. In the published preclinical work, oral gavage in mice has used 0.025–4 mg/kg body weight in liver-protection studies; cell culture studies have used 0.15–15 micromolar concentrations; and the single ovarian cancer xenograft study injected 0.2 mL of a 0.25 or 0.50 g/L solution intraperitoneally every other day. Any human-equivalent dose is pure extrapolation and not supported by clinical data.
Frequency
In the liver studies, mice were dosed by mouth once a day for 10 days (acute injury) or 12 weeks (fatty liver); in the xenograft study, injections were given every other day for four weeks. No human frequency is established.
Timing Considerations
No specific timing requirements: can be administered at any time of day, with or without food, and is not tied to exercise timing. Consistency matters more than the specific clock — dose at roughly the same time each day (or same day each week, for weekly protocols) to keep exposure steady.
Cycle Length
No human cycle convention exists. Animal experiments have used continuous dosing — daily by mouth, or every other day by injection — across the experimental window rather than cyclic protocols.
Protocol Notes
Critical context: PGPIPN is a research compound, not a therapeutic product. It is not commercially available as a peptide therapeutic, is not sold by mainstream peptide vendors as a finished product, and has no clinician-facing protocol. The proline-rich structure does plausibly support oral bioavailability — the three proline residues out of six make the backbone unusually resistant to gastrointestinal peptidase cleavage — but actual human pharmacokinetic data is absent. Anyone considering use of PGPIPN outside of a research setting should understand that they are extrapolating from cell-culture and rodent studies in a small body of work originating from one research group, with no human safety, dosing, or efficacy data to anchor to. This is fundamentally a candidate compound rather than a usable therapeutic.
PGPIPN is not FDA-approved for any indication. The preclinical anticancer and hepatoprotective findings are mechanistically interesting but do not justify use in any human clinical context, particularly not as a substitute for evidence-based oncology care or hepatology management.
Timeline of Effects
Onset
No characterized onset profile in humans. In rodent ovarian cancer xenograft studies, tumor growth suppression became apparent over weeks of continuous dosing. In acute alcoholic liver injury models, hepatoprotective effects were seen after 10 days of daily oral pretreatment, with the alcohol binges given on the last three days.
Peak Effect
In xenograft studies, maximal tumor volume reduction (around 68% at the highest dose) was observed at the end of the multi-week dosing window. In liver injury models, peak hepatoprotective biomarker effects were measured at end-of-experiment timepoints. No human peak-effect data exists.
After Discontinuation
Not characterized. No plasma half-life has been published for any species. The only blood-level figure anywhere is an unpublished mouse reading of about 84 ng/mL an hour after an oral dose, mentioned in passing as data not shown. Effects on tumor or liver biomarkers in animal models likely fade after dosing stops, but this has not been systematically tracked in published work.
Common Questions
Where does PGPIPN come from?
PGPIPN is a fragment of bovine beta-casein, one of the main proteins in cow's milk. It corresponds to amino acid positions 63-68 and is released when beta-casein is broken down by digestive enzymes. It belongs to a broader class of bioactive peptides hidden within food proteins that become active only after proteolytic release.
Why is PGPIPN resistant to digestion?
PGPIPN contains three proline residues out of its six amino acids. Proline's rigid ring structure makes the peptide backbone difficult for most proteases to cleave, allowing the intact hexapeptide to survive gastrointestinal digestion and potentially reach the bloodstream after oral administration.
Is PGPIPN toxic to normal cells?
In laboratory studies, PGPIPN showed minimal toxicity toward normal cells. In the 2013 study it had no effect on the growth of LO2 cells, described there as normal liver cells, though the LO2 line has since been shown to be a HeLa (cervical cancer) derivative. It slowed the growth of p53-knockout mouse embryo fibroblasts only at a high dose. A 2021 study reported that combining PGPIPN with cisplatin had no effect on normal ovarian epithelial cells cultured from six women. This selective toxicity toward cancer cells over normal cells is one of its most promising features, though human safety data is lacking.
How does PGPIPN compare to conventional chemotherapy drugs?
In one 2013 xenograft study (six mice per group, peptide injected into the abdomen), high-dose PGPIPN reduced ovarian tumor volume by about 68%, which actually exceeded the 42% reduction seen with 5-fluorouracil in the same study. No head-to-head test against cisplatin has been published. The same research group later wrote that PGPIPN's anticancer effects are significantly lower than those of standard drugs such as paclitaxel and 5-fluorouracil. Its advantage lies in low toxicity to normal cells — researchers have explored combining it with cisplatin to overcome drug resistance rather than replacing chemotherapy entirely.
Is PGPIPN in all cow's milk? What about A1 versus A2?
PGPIPN is residues 63 to 68 of mature bovine beta-casein, and it sits inside the same stretch of the protein that produces beta-casomorphin-7, the opioid fragment at the centre of the A1-versus-A2 milk debate. Residue 67 is a proline in A2-type beta-casein, which yields PGPIPN, but a histidine in the A1 and B variants, which would yield PGPIHN instead. A2-type beta-casein is therefore the source of the intact sequence.
Is PGPIPN found in foods like kefir or cheese?
Yes, in small amounts, as a fragment released by fermentation or digestion. Peptide-profiling studies have identified it in kefir but not in the unfermented milk it was made from, in 12-month-ripened Parmigiano Reggiano, and in laboratory-digested whey protein. It has also been detected in the small intestine of healthy adults after they consumed casein. None of these studies measured whether any of it reaches the bloodstream, and none of them is a study of health effects.
How potent is PGPIPN against cancer cells in the laboratory?
In primary ovarian cancer cells taken from patients, the concentration needed to halve cell viability was 14.5 mg/L at 24 hours, 9.3 mg/L at 48 hours and 1.24 mg/L at 72 hours. The same group reports this is weaker than a laboratory-designed fusion peptide they built from it, and weaker than standard chemotherapy drugs.
Is PGPIPN available as a supplement or peptide therapeutic?
No. PGPIPN is exclusively a research compound. It is not FDA-approved for any indication, is not sold by mainstream peptide vendors as a finished therapeutic, and has no clinician-facing protocol. Some research-chemical suppliers offer synthetic PGPIPN for laboratory use only, not for human consumption. There is no established human dose, no human pharmacokinetic data, and no clinical safety record.
Why hasn't PGPIPN entered human clinical trials?
The biggest structural reason is that nearly all of the preclinical efficacy and mechanistic work traces back to a single research program at Anhui Medical University in China. Independent multi-laboratory replication, formal toxicology to regulatory standards, and the funding required for a first-in-human study have not materialized. Until those gaps are filled, PGPIPN remains a candidate molecule of mechanistic interest rather than a translational program with a clear clinical path.
Who PGPIPN Is NOT For
- •Active malignancy under treatment — despite preclinical anticancer signal, layering an unstudied investigational peptide onto active oncology care has no safety basis and could complicate response assessment or interact unpredictably with chemotherapy regimens.
- •Active liver disease requiring clinical management — PGPIPN's preclinical hepatoprotective data should not be substituted for hepatology evaluation.
- •Pregnancy — no reproductive-toxicology data; not recommended.
- •Breastfeeding — no data on transfer or infant exposure.
- •Pediatric use — no pediatric safety or developmental data.
- •Known milk-protein allergy — although PGPIPN is a defined synthetic sequence and not a milk-protein extract, hypersensitivity in patients with severe casein allergy has not been studied and warrants caution.
Drug & Supplement Interactions
There are no documented clinical drug interactions for PGPIPN because no human pharmacovigilance studies exist. What follows is theoretical and derived from the preclinical mechanistic work. The most consequential theoretical interaction is with cisplatin and other platinum-based chemotherapy. The published rationale for PGPIPN in ovarian cancer is precisely a cisplatin-sensitization effect via HSF1/HSP70 pathway downregulation; this is positioned as a synergistic interaction in the Anhui Medical University research, but synergy in cell culture does not establish clinically safe co-administration, and the in vivo pharmacology of combined exposure has not been characterized in humans. Concurrent use during any chemotherapy regimen should not be undertaken outside a formal clinical trial. Theoretical interactions also exist with other HSP70-modulating investigational agents and with immunomodulatory therapy given the macrophage and lymphocyte effects observed in immunology models. CYP-mediated interactions are not described and at the small doses involved are unlikely. Patients on any regular medication should disclose investigational peptide use to their prescribing clinician, though again, PGPIPN is not realistically encountered as a finished therapeutic product.
Safety Profile
Common Side Effects
Cautions
- • Not FDA-approved for any indication
- • No human clinical trials have been conducted
- • All data comes from cell culture and animal models
- • Optimal human dosing is completely unknown
What We Don't Know
Human safety, pharmacokinetics, and efficacy are entirely unestablished. All research to date has been preclinical (in vitro and animal studies), primarily from a single research group at Anhui Medical University in China. No human clinical trials have been published.
Legal Status
United States
Not FDA-approved for any indication. Not approved as a drug, dietary supplement ingredient, or food additive — though, as a natural fragment of milk protein, it occurs in fermented and aged dairy foods and forms during digestion. PGPIPN is exclusively a research compound and is not commercially available as a finished therapeutic product.
International
Not approved as a medicine in any regulatory jurisdiction. Not on the EMA, MHRA, TGA, or Health Canada lists of approved peptide therapeutics. Some research-chemical suppliers sell synthetic PGPIPN for laboratory use, not for human consumption.
Sports & Competition
Not named on the WADA Prohibited List. Because it is not approved by any governmental health authority for human therapeutic use, injectable PGPIPN would fall under WADA's S0 catch-all category for unapproved substances. The point is largely academic given that PGPIPN is not commonly used in athletic or supplement contexts.
Regulatory status changes over time. Verify current local rules with a qualified professional.
Myths & Misconceptions
Myth
PGPIPN is a proven natural anticancer agent because it comes from milk.
Reality
It is a candidate molecule based on cell-culture and rodent xenograft data from one research program. Calling it a 'proven' anticancer agent — or a natural one in any therapeutically meaningful sense — overstates the evidence by orders of magnitude. Milk origin tells you about its biochemical lineage, not about its safety or efficacy in humans.
Myth
PGPIPN is simply an immune booster.
Reality
The direction of the effect depends on the cell type and the setting. Early mouse and rat work reported stronger macrophage and lymphocyte activity. The one independent study, from a Greek group working in macrophages from newly weaned piglets, found the opposite: PGPIPN suppressed the urokinase system and superoxide output, and had no effect at all in cells from older piglets. Immunomodulatory is a more accurate word than immune-boosting.
Myth
PGPIPN is proven to be absorbed when you swallow it.
Reality
The only evidence of oral absorption is a single unpublished measurement of about 84 ng/mL in mouse blood an hour after dosing, mentioned as data not shown. Its proline-rich structure makes resistance to digestion plausible, and the peptide has been found in human intestinal fluid after casein intake, but no human blood level has ever been measured.
Myth
Drinking milk delivers therapeutic doses of PGPIPN.
Reality
PGPIPN is encrypted within beta-casein and released only when the parent protein is digested by specific proteolytic conditions. Whether dietary milk consumption yields any meaningful systemic exposure to the intact hexapeptide in humans has not been quantified, and the doses used in animal studies are not realistically achievable through dietary intake. It has been detected in human small-intestine fluid after casein intake, but only in a small fraction of samples. And it can only form from A2-type beta-casein: in A1 and B variants, position 67 is a histidine rather than a proline, so the corresponding fragment would be PGPIHN.
Myth
PGPIPN can replace cisplatin in ovarian cancer treatment.
Reality
The published rationale is that PGPIPN may resensitize cisplatin-resistant cells, not replace cisplatin. Even that resensitization claim comes from cell-culture work only; no human clinical trial has tested PGPIPN in any oncology indication. Substituting it for evidence-based oncology care would be dangerous.
Myth
PGPIPN is safe because preclinical studies showed minimal normal-cell toxicity.
Reality
Preliminary normal-cell-line data is encouraging but does not establish in vivo safety across organ systems, in long-term dosing, or in human physiology. No formal toxicology study to regulatory standards has been performed.
Published Research
13 studiesBioactive hexapeptide reduced the resistance of ovarian cancer cells to DDP by affecting HSF1/HSP70 signaling pathway
Peptide Profiling and Biological Activities of 12-Month Ripened Parmigiano Reggiano Cheese.
Milk-derived hexapeptide PGPIPN prevents and attenuates acute alcoholic liver injury in mice by reducing endoplasmic reticulum stress
Therapeutic hexapeptide (PGPIPN) prevents and cures alcoholic fatty liver disease by affecting the expressions of genes related with lipid metabolism and oxidative stress
PGPIPN prevented and treated alcohol-induced fatty liver in mice via ACC/PPAR-gamma modulation and oxidative stress reduction.
Systematic Review of the Gastrointestinal Effects of A1 Compared with A2 β-Casein.
Construction of an anticancer fusion peptide (ACFP) derived from milk proteins and an assay of anti-ovarian cancer cells in vitro
The milk-derived fusion peptide ACFP suppresses the growth of primary human ovarian cancer cells by regulating apoptotic gene expression and signaling pathways
The milk-derived hexapeptide PGPIPN inhibits the invasion and migration of human ovarian cancer cells by regulating the expression of MTA1 and NM23H1 genes
Peptidomic analysis reveals proteolytic activity of kefir microorganisms on bovine milk proteins.
PGPIPN, a therapeutic hexapeptide, suppressed human ovarian cancer growth by targeting BCL2
Demonstrated PGPIPN inhibits SKOV3 proliferation and induces apoptosis via BCL2 downregulation; 68% tumor reduction in xenograft mice.
Sequential release of milk protein-derived bioactive peptides in the jejunum in healthy humans.
The effect of two bovine beta-casein peptides on various functional properties of porcine macrophages and neutrophils: differential roles of protein kinase A and exchange protein directly activated by cyclic AMP-1.
The only independent primary study of PGPIPN. In macrophages from newly weaned piglets, the hexapeptide suppressed rather than stimulated the urokinase plasminogen activator system and superoxide production — a reminder that its immune effect depends on cell type and context.
Biologically active casein peptides implicated in immunomodulation.
Quick Facts
- Class
- Milk-Derived Bioactive Hexapeptide
- Tier
- D
- Evidence
- Preliminary
- Safety
- Limited Data
- Updated
- Sep 2026
- Citations
- 13PubMed
Also known as
Tags
Related Goals
Evidence Score
Clinical Trials
View Clinical TrialsLinks to ClinicalTrials.gov for reference. Listing does not imply endorsement.